ABMD - Abiomed shares fall after Q3 earnings results FY forecast

Abiomed shares fall (ABMD -4.7%) after the company posted third-quarter revenue that was in line with Wall Street estimates. The company's quarterly revenue increased 18% to $248.1M, in line with analysts' average estimate, helped by the performance of its Impella heart pump business. Worldwide Impella heart pump product revenue for the quarter totaled $235.8M, an increase of 18% compared to the same period last year. Gross margin for the quarter was 82.3% compared to 81.5% last year. The company expects 2022 revenue to be in the range of $1,010M to $1,030M, slightly above the original guidance. Also expects fiscal year 2022 non-GAAP operating margin to be in the range of 24% - 25%.

For further details see:

Abiomed shares fall after Q3 earnings results, FY forecast